Context Therapeutics Inc. (CNTX) earnings
CNTX earnings moved a median of -2.47% by the close. Quarterly and annual CNTX reports and results, each read against the price at its own news timestamp. Back to the CNTX overview →
21 measured CNTX earnings events.
Where these CNTX earnings landedvs 21 measured CNTX earnings reactions
| Middle 50% of CNTX earnings reactions | -3.60% to -0.20% |
|---|---|
| Median reaction (to close) | -2.47% |
| Measured reactions | 21 |
Point-in-time · zero look-ahead
Half of the 21 CNTX earnings events with a measured close landed between -3.60% and -0.20%; 24% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress | Press release | +4.42% | -0.20% | |
| Form 10-Q Context Therapeutics For: Jun 30 | SEC filing · Form 10-Q | +4.42% | -0.20% | |
| Context Therapeutics Reports First Quarter 2026 Operating and Financial Results | Press release | -2.09% | -2.51% | |
| Form 10-Q Context Therapeutics For: Mar 31 | SEC filing · Form 10-Q | -2.09% | -2.51% | |
| Form 10-K Context Therapeutics For: Dec 31 | SEC filing · Form 10-K | -4.88% | -3.05% | |
| Context Therapeutics Reports Third Quarter 2025 Operating and Financial Results | Press release | -1.35% | -3.60% | |
| Form 10-Q Context Therapeutics For: Sep 30 | SEC filing · Form 10-Q | -1.35% | -3.60% | |
| Context Therapeutics Reports Second Quarter 2025 Operating and Financial Results | Press release | -0.65% | -0.80% | |
| Form 10-Q Context Therapeutics For: Jun 30 | SEC filing · Form 10-Q | -0.65% | -0.80% | |
| Context Therapeutics Reports First Quarter 2025 Operating and Financial Results | Press release | -8.95% | -8.93% | |
| Form 10-Q Context Therapeutics For: Mar 31 | SEC filing · Form 10-Q | -8.95% | -8.93% | |
| Form 10-K Context Therapeutics For: Dec 31 | SEC filing · Form 10-K | +3.08% | +0.23% | |
| Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results | Press release | -1.33% | -7.11% | |
| Form 10-Q Context Therapeutics For: Sep 30 | SEC filing · Form 10-Q | -1.33% | -7.11% | |
| Context Therapeutics Reports Second Quarter 2024 Operating and Financial Results | Press release | -0.63% | +1.27% | |
| Form 10-Q Context Therapeutics For: Jun 30 | SEC filing · Form 10-Q | -0.63% | +1.27% | |
| Context Therapeutics Reports First Quarter 2024 Operating and Financial Results | Press release | +0.55% | +0.55% | |
| Form 10-Q Context Therapeutics For: Mar 31 | SEC filing · Form 10-Q | +0.55% | +0.55% | |
| Form 10-K Context Therapeutics For: Dec 31 | SEC filing · Form 10-K | +2.59% | -7.76% | |
| Context Therapeutics Reports Third Quarter 2023 Operating and Financial Results | Press release | — | -2.47% | |
| Form 10-Q Context Therapeutics For: Sep 30 | SEC filing · Form 10-Q | — | -2.47% |
Keep exploring
More CNTX: analyst actions → · SEC filings → · CNTX overview →